- Trials with a EudraCT protocol (6)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
6 result(s) found for: hereditary angioedema.
Displaying page 1 of 1.
EudraCT Number: 2010-019670-32 | Sponsor Protocol Number: B1 | Start Date*: 2013-01-31 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE) | |||||||||||||
Full Title: Pharmacokinetics and Safety of Human Pasteurised C1-Inhibitor Concentrate (Berinert/CE1145) in Subjects with Congenital C1-INH Deficiency and Frequent Hereditary Angioedema (HAE) Attacks. | |||||||||||||
Medical condition: Hereditary Angioedema (HAE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003918-12 | Sponsor Protocol Number: CSL312_3002 | Start Date*: 2021-06-08 | |||||||||||
Sponsor Name:CSL Behring LLC | |||||||||||||
Full Title: An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | |||||||||||||
Medical condition: Hereditary angioedema | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) CZ (Trial now transitioned) HU (Trial now transitioned) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006906-58 | Sponsor Protocol Number: PHA022121-C303 | Start Date*: 2022-07-01 | ||||||||||||||||||||||||||
Sponsor Name:Pharvaris Netherlands BV | ||||||||||||||||||||||||||||
Full Title: A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency (Type I or Type II) | ||||||||||||||||||||||||||||
Medical condition: Hereditary angioedema attacks caused by Type 1 and 2 C1-Inhibitor Deficiency | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) FR (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000757-93 | Sponsor Protocol Number: ISIS721744-CS7 | Start Date*: 2022-09-05 | |||||||||||
Sponsor Name:IONIS PHARMACEUTICALS, INC. | |||||||||||||
Full Title: An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) | |||||||||||||
Medical condition: Hereditary Angioedema (HAE) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) NL (Ongoing) DK (Completed) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005932-50 | Sponsor Protocol Number: BCX7353-304 | Start Date*: 2022-10-05 | |||||||||||
Sponsor Name:BioCryst Pharmaceuticals, Inc. | |||||||||||||
Full Title: A PHASE 3 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF BEROTRALSTAT PROPHYLAXIS IN CHILDREN WITH HEREDITARY ANGIOEDEMA WHO ARE 2 TO < 12 YEARS OF AGE | |||||||||||||
Medical condition: Hereditary Angioedema (HAE) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) AT (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001176-42 | Sponsor Protocol Number: KVD900-302 | Start Date*: 2022-09-30 | ||||||||||||||||
Sponsor Name:KalVista Pharmaceuticals Ltd | ||||||||||||||||||
Full Title: An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients with He... | ||||||||||||||||||
Medical condition: Hereditary Angioedema Type I or II | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GR (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) BG (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) DE (Ongoing) PT (Trial now transitioned) SK (Trial now transitioned) RO (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
